HP 228

Drug Profile

HP 228

Latest Information Update: 13 Aug 2002

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SYGNIS Pharma
  • Developer Dura Pharmaceuticals; SYGNIS Pharma
  • Class Peptides
  • Mechanism of Action Immunomodulators; Interleukin 10 stimulants; Melanocortin receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Asthma; Chemotherapy-induced damage; Inflammation; Obesity; Postoperative pain; Type 2 diabetes mellitus

Most Recent Events

  • 13 Aug 2002 Discontinued - Phase-I for Asthma in USA (Inhalation)
  • 13 Aug 2002 Discontinued - Phase-I for Inflammation in USA (Inhalation)
  • 13 Aug 2002 Discontinued - Phase-II for Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top